Tanaka, Kazuhiro http://orcid.org/0000-0002-5138-8952
Machida, Ryunosuke
Kawai, Akira
Nakayama, Robert
Tsukushi, Satoshi
Asanuma, Kunihiro
Matsumoto, Yoshihiro
Hiraga, Hiroaki
Hiraoka, Koji
Watanuki, Munenori
Yonemoto, Tsukasa
Abe, Satoshi
Katagiri, Hirohisa
Nishida, Yoshihiro http://orcid.org/0000-0002-7511-6388
Nagano, Akihito
Suehara, Yoshiyuki
Kawashima, Hiroyuki
Kawano, Masanori
Morii, Takeshi
Hatano, Hiroshi
Toguchida, Junya
Okuma, Tomotake
Takeyama, Masanobu
Takenaka, Satoshi
Akisue, Toshihiro
Furuta, Taisuke
Emori, Makoto
Hiruma, Toru
Outani, Hidetatsu
Yamamoto, Tetsuji
Kataoka, Tomoko
Fukuda, Haruhiko
Ozaki, Toshifumi
Iwamoto, Yukihide
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP17ck0106336 and JP20ck0106614)
National Cancer Center Research and Development Fund
Article History
Received: 28 April 2022
Revised: 22 June 2022
Accepted: 29 June 2022
First Online: 23 July 2022
Competing interests
: KT received honoraria from Taiho Pharmaceutical, Eisai, and Novartis. AK received honoraria from Lilly, Taiho Pharmaceutical, Eisai, Novartis, and Otsuka Pharmaceutical. H Hiraga received honoraria from Taiho Pharmaceutical, Daiichi-Sankyo, and Novartis. YS received honoraria from Bayer AG, and a grant from LOXO Oncology. HF received honoraria from Chugai Pharmaceutical. The other authors declare that they have no conflicts of interest.
: All patients provided written informed consent to participate in this study. The study was approved by each participating institution’s Institutional Review Board. This study was performed in accordance with the Declaration of Helsinki.
: Not applicable.